Abstract: A display method and apparatus, a wearable device, and a computer-readable storage medium. The method is applied to the wearable device. The wearable device comprises an inertial sensor and at least two screen display areas; when a user wears the wearable device, the screen display areas are not located on the same plane at the same time. The method comprises: obtaining a target action of a user by means of measurement data collected by the inertial sensor; determining the screen display area corresponding to a sight range of the user according to the target action of the user; and lighting the screen display area to display the current content.

Abstract: A display method and apparatus, a wearable device, and a computer-readable storage medium are provided. The method is applied to the wearable device. The wearable device comprises at least two touchable screen display areas. The method comprises: displaying current content on a lightened screen display area; and adjusting the current content displayed on the lightened screen display area according to a touch event on another non-lightened screen display area. The reading and interaction processes of users do not conflict with each other.

Abstract: Chlorogenic acid and/or coumaroylquinic acid are employed in preparation of drugs for treating squamous cell carcinoma. Chlorogenic acid or coumaroylquinic acid can effectively treat squamous cell carcinoma. A combination of chlorogenic acid and coumaroylquinic acid can also achieve effective treatment, can yield a synergistic effect, and has excellent application prospect.

Abstract: Chlorogenic acid or compositions containing chlorogenic acid are used in preparation of a medicament for treating sarcoma. The chlorogenic acid composition includes chlorogenic acid and coumaroyl quinic acid, can effectively treat sarcoma, and has a better therapeutic effect than the chemotherapeutic medicament doxorubicin. The experimental results show that the combination of chlorogenic acid and coumaroylquinic acid can have a synergistic effect.

Abstract: A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

Abstract: An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.

Abstract: Chlorogenic are used in preparing a drug for preventing or blocking brain and/or bone metastases of lung cancer. The chlorogenic acid can effectively prevent or block metastasis of tumor cells of a patient with lung cancer, such as small cell lung cancer, squamous cell lung cancer, and lung adenocarcinoma.

Abstract: A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Abstract: Methods and apparatuses for adjusting a game scene are set forth herein. The method includes receiving heart rate information of a user, wherein the user wears the computing device to play the game, and based on the received heart rate information of the user, adjusting at least one element in the game scene of the game. By using a smart wearable device to acquire the heart rate information of the user playing the game, the game scene of the game can be adjusted according to the heart rate information. Therefore, the game can be made to be more interesting by receiving multi-dimensional interaction information of the user.

Abstract: A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.

Abstract: A method includes: receiving sensor data representing a subject within a field of vision associated with respective ones of a plurality of modular cameras associated with a composite camera and one or more geo-spatial characteristics associated with respective ones of the plurality of modular cameras; determining an arrangement of the composite camera based on the sensor data; generating digital content for respective ones of the plurality of modular cameras based on the sensor data; and generating combined digital content that represents a subject within a field of vision associated with the composite camera based on the digital content and the arrangement of the composite camera, wherein the field of vision associated with the composite camera includes at least some of fields of vision associated with the plurality of modular cameras.

Abstract: A method for processing electrocardiograph (ECG) data using a garment includes determining, by a processor, a current working lead from ECG leads formed in advance using flexible electrodes in the garment based on a current ECG monitor type, and receiving, by the processor through lead wires corresponding to the current working lead, ECG data collected by flexible electrodes corresponding to the current working lead. A wearable apparatus for processing ECG data includes at least two flexible electrodes, in which the at least two flexible electrodes are capable of forming different leads based on predetermined configurations, at least two lead wires, and an ECG data collector configured to receive ECG data collected by the at least two flexible electrodes, in which each of the at least two flexible electrodes connects to the ECG data collector via at least one of the at least two lead wires.

Abstract: Methods, apparatuses and wearable devices for measuring an ECG signal for a user wearing a wearable device includes when the ECG signal is measured in a first mode, receiving the ECG signal by an ECG sensor from a closed circuit formed by a first ECG sensor electrode and a second ECG sensor electrode, in which the wearable device includes a main body detachable to the wearable device, a connecting portion, and electrode patches, and the main body includes the ECG sensor, the first ECG sensor electrode, and the second ECG sensor electrode, and when the ECG signal is measured in a second mode, receiving the ECG signal by the ECG sensor from a closed circuit formed by electrodes of the electrode patches, in which the ECG sensor is in the main body and the main body is connected to the electrode patches.

Abstract: A preparation containing a chlorogenic acid crystal form. The crystal form is an orthorhombic crystal system, a space group is P212121, cell parameters are as follows: a=7.7291(2)?, b=10.9808(2)?, c=36.5334(7)?, ?=?=?=90.00°, Z=8, and a cell volume is 3100.65(11)?3. The content of the chlorogenic acid crystal form in the preparation is 10-5000 mg/g. The preparation is advantageous to bioavailability, and can be used for preparing medicines for treating tumor, psoriasis and other immune system diseases, resisting oxidation, protecting liver and gallbladder, treating cardiovascular diseases, and resisting viruses.

Abstract: The present invention provides an application of chlorogenic acid in preparing medicines for treating melanoma and a pharmaceutical composition comprising chlorogenic acid and used for treating melanoma.

Abstract: Provided is a crystalline form of chlorogenic acid. The crystalline form is an orthorhombic crystal system, the space group is P212121, the cell parameters are a=7.7291 (2) ?, b=10.9808 (2) ?, and c=3.5334 (7) ?, ?=?=?=90.00°, Z=8, and the cell volume is 3100.65 (11) ?3. Also provided is a preparation method for the crystalline form. The present crystalline form has good stability and does not significantly change during storage for 48 months in a cool, dark place, and the various indices all meet the relevant requirements for active pharmaceutical ingredients. The crystallization process provided by the present invention can not only use raw materials having different purities to prepare the same crystalline form of chlorogenic acid, but can also significantly reduce solvent residue in the raw materials, thereby improving product safety.

Abstract: The pharmaceutical composition is a formulation prepared by the raw materials in parts by weight: 1-300 parts of chlorogenic acid and 1-50 parts of Ganoderma lucidum spore oil, and the preparative process for said pharmaceutical composition was provided. Chlorogenic acid can be used compatibly with Ganoderma lucidum spore oil, with a synergistic effect. Inclusion technique is applied in product development to improve stability of oily liquid material Ganoderma lucidum spore oil and solid material chlorogenic acid obtained from the extract of Eucommia leaves. After inclusion by the inclusion technology, the liquid drugs become powder, and thus easily oxidized natural products could be protected. Moreover, the damage for active ingredients caused by air can be prevented, and the stability and the taste may get improved.

Abstract: Methods and apparatuses for adjusting a game scene are set forth herein. The method includes receiving heart rate information of a user, wherein the user wears the computing device to play the game, and based on the received heart rate information of the user, adjusting at least one element in the game scene of the game. By using a smart wearable device to acquire the heart rate information of the user playing the game, the game scene of the game can be adjusted according to the heart rate information. Therefore, the game can be made to be more interesting by receiving multi-dimensional interaction information of the user.

Abstract: The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.